Professor Rafal Dziadziuszko completed his training in Radiotherapy (2001) and Medical Oncology (2004) at the Department of Oncology and Radiotherapy of the Medical University of Gdańsk, Poland.
He subsequently completed a translational cancer research fellowship at the University of Colorado Cancer Center. Between 2005 and 2007 he worked on predictive assays for EGFR targeted therapies in lung cancer, including immunohistochemistry, gene copy number, and activating mutations.
His fellowship was funded by the International Union Against Cancer and the International Association for the Study of Lung Cancer. He then returned to his home institution to serve as a deputy chair of the department.
Prof. Dziadziuszko’s main interests include lung cancer translational and clinical research, and he is a co-author of over 120 peer-reviewed articles and book chapters on this topic, including the Lung Cancer chapter in a recent edition of Oxford Textbook of Oncology.
He is a member of the European Society for Medical Oncology, International Association for the Study of Lung Cancer, European Organisation for Research and Treatment of Cancer – Lung Cancer and Radiotherapy Groups, European Society for Radiotherapy and Oncology, American Society of Clinical Oncology, and American Association for Cancer Research. He has also participated in the organisation of several academic clinical research studies in Poland and Central Europe and serves as the Vice-Chairman of the Central and East European Oncology Group.
His current work includes identification of novel molecular targets for early lung cancer trials, evaluation of novel radiotherapy strategies in thoracic malignancies and research on lung cancer screening programs. He has been involved in EGFR, IGF-1R, HER2, ALK, ROS1, MET and immune checkpoint translational and clinical research. He is a mentor of six past and ongoing PhD students.
ESMO 2017 Congress
Rafal Dziadziuszko was the NSCLC (metastatic) Track Chair of the ESMO 2017 Congress, which took place in Madrid, Spain (8-12 September 2017).